|
|
|
|
|
16.01.26 - 14:01
|
Invitation to digital meeting focusing on novel strategies for treating bacterial infections without antibiotics (Cision)
|
|
|
Welcome to Hamlet BioPharma's monthly digital meeting on January 21 at 12:00, held the same day as the Davos Summit discusses ''The Fragile Future of Antibiotics. ''
[image]
As stated in the Davos Summit Program: “Antimicrobial resistance (AMR) is already undermining modern medicine. As superbugs evolve faster than new treatments can be developed, once-manageable infections are becoming harder to cure, threatening everything from surgery to cancer care. How can we ensure global access to life-saving antibiotics while preserving their effectiveness for generations to come?”
https://www....
|
|
|
16.01.26 - 10:24
|
Spermosens and Sapyen sign Memorandum of Understanding to advance male fertility diagnostics (Cision)
|
|
|
Spermosens AB has entered into a Memorandum of Understanding (MoU) with Sapyen, a global male fertility diagnostics company with operations across the US, Europe, UK and Australia. The MoU reflects the parties' intention to evaluate a potential collaboration with the aim of establishing a partner-led commercialization model for Spermosens' diagnostic method, JUNO-Checked.
Male fertility diagnostics is undergoing a structural shift, driven by increasing demand for patient-friendly access combined with clinical-grade data. Sapyen has established a model that enables home-based sample...
|
|
|
16.01.26 - 09:18
|
Regulatory Approval for ARIA Monitoring Strengthens SyntheticMR′s Position with a Broader Neuroimaging Offering (Cision)
|
|
|
SyntheticMR AB (publ), a global leader in quantitative MRI software, today announced continued portfolio and commercial progress following its acquisition of Combinostics Oy in early 2025.
The integration has established SyntheticMR as one unified company with a broader offering and a strengthened position in the growing neurodegenerative disease imaging segment.
cNeuro® cMRI has been integrated into SyntheticMR's product portfolio, expanding the company's capabilities in quantitative and AI-driven neuroimaging. Together with SyMRI®, the combined portfolio delivers comprehensive...
|
|
|
16.01.26 - 07:48
|
Cereno Scientific: Invitation to Capital Markets Day 2026 (Cision)
|
|
|
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced an invitation to its Capital Markets Day on February 5, 2026, in Stockholm.
The Capital Markets Day will provide investors, analysts and financial media with an update on Cereno Scientific's clinical development program, strategic priorities and growth ambitions. The program will include presentations from the company's management as well as contributions from external speakers with relevant...
|
|
|
|
|
|
|
15.01.26 - 14:01
|
Six-year data demonstrate a durable disease-modifying effect of ProTrans in type 1 diabetes (Cision)
|
|
|
NextCell Pharma AB (“NextCell” or the “Company”) today announces that six-year follow-up data indicate that a single infusion of ProTrans provides a long-lasting and clinically relevant preservation of endogenous insulin production in patients with newly-diagnosed type 1 diabetes. Patients treated with ProTrans continue to exhibit clinically relevant levels of stimulated C-peptide well beyond expected levels as seen with the natural course of the disease.
· Durable effect ≥6 years
· Approximately 50% of insulin-producing function preserved
· Strategy confirmed: a single infusion may be...
|
|
|
|
|
|
|
15.01.26 - 11:42
|
Invitation to presentation in connection with EQL Pharma′s interim report, third quarter, 2025/26 (Cision)
|
|
|
EQL Pharma AB (publ) will publish its interim report for the third quarter, 2025/26, on Tuesday, February 3[rd].
At 10.00 (CET) 4[th] February, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. CEO and President Axel Schörling presents and comments on the interim report. After the presentation, there is an opportunity to ask questions for those who participate.
Use the following link to access the virtual meeting: https://tinyurl.com/mpmbyxxn
Date and time
February 4[th], 2026, at 10.00 (CET) the...
|
|
|
15.01.26 - 08:48
|
SyntheticMR AB announces intention to publish financial guidance ahead of upcoming rights issue (Cision)
|
|
|
SyntheticMR AB (publ) (“SyntheticMR”) hereby announces that the company intends to publish financial guidance ahead of the upcoming rights issue of approximately SEK 32.8 million (the “Rights Issue”).
Financial guidance
In addition to an information document prepared in accordance with Article 1.4 db of Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Information Document”), SyntheticMR has decided to publish financial guidance as of 19 January 2026 in order to disclose available preliminary figures ahead of the Rights Issue. These preliminary figures will be...
|
|
|
15.01.26 - 08:36
|
Egoo Health achieves breakthrough precision in key diabetes biomarker test, paving the way for partnerships (Cision)
|
|
|
Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, together with its partner Hipro Biotechnology Co., Ltd. (“Hipro”), announces a major milestone: the Egoo HbA1c blood test for diabetes management has achieved best-in-class precision with a coefficient of variation (CV) below 3%. This achievement positions Egoo optimally for partnering and commercialisation potentially, the first home-use HbA1c test to meet the same stringent clinical and regulatory standards as central laboratory testing.
Managing diabetes at home requires solutions that are accurate,...
|
|
|
|
|
|
|
14.01.26 - 08:31
|
The subscription period in Peptonic′s rights issue of units starts today (Cision)
|
|
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES.
Today, 14 January 2026, the subscription period begins in Peptonic Medical AB (publ) (”Peptonic” or the “Company”) rights issue of units, consisting of shares and warrants, which forms...
|
|
|
13.01.26 - 11:54
|
Update on Bankruptcy Proceedings (Cision)
|
|
|
Lund, Sweden – January 13, 2026 – The Lund District Court has today accepted Phase Holographic Imaging PHI AB's bankruptcy filing. As part of the process, the court has appointed Niklas Ernulf as bankruptcy trustee. The trustee will oversee the management of the company's assets and liabilities, and ensure an orderly liquidation in accordance with applicable law.
PHI will cooperate fully with the trustee to facilitate the process and keep stakeholders informed of significant developments....
|
|
|
|
|
13.01.26 - 10:48
|
Peptonic publishes prospectus in connection with rights issue of units (Cision)
|
|
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES.
Peptonic Medical AB (publ) (”Peptonic” or the “Company”) has prepared an EU growth prospectus (the “Prospectus”) in connection with the Company's forthcoming rights issue of units,...
|
|
|
13.01.26 - 08:33
|
The subscription period in Karolinska Development AB (publ)′s rights issue begins today (GlobeNewswire EN)
|
|
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO, OR INVITATION TO, ACQUIRE OR SUBSCRIBE FOR ANY SECURITIES IN KAROLINSKA DEVELOPMENT AB (PUBL) IN ANY JURISDICTION. PLEASE ALSO REFER TO THE SECTION “IMPORTANT INFORMATION” BELOW....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
